Eisai provides updates on JHU and Broad deals

Eisai Co. Ltd. (Tokyo:4523) announced updates to separate deals with The Johns Hopkins University (Baltimore, Md.) and Broad Institute of MIT and Harvard (Cambridge, Mass.). Under the first deal, Johns Hopkins granted Eisai exclusive rights to develop and commercialize IP and small molecules discovered under a 2011 deal to identify compounds for neurological and oncology indications. The university will receive $500,000 upfront and is eligible for undisclosed milestones and royalties. Eisai will provide a further $500,000 to support future Johns Hopkins Drug Discovery research (see BioCentury, Oct. 24, 2011)...